Back to Peptides
Adamax
Neuroprotective & Cognitive EnhancersAdamax is a next-generation nootropic peptide and enhanced Semax analog featuring N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration. It upregulates BDNF, enhances TrkB receptor sensitivity, modulates monoamines, and provides neuroprotection against oxidative stress and excitotoxicity.
Reconstitute
3 mL BAC + 10mg vial
33 mcg/unit
Daily Range
300–1000 mcg Intranasal Spray
daily
Standard Dose
500 mcg
Cycle
4–8 weeks
then reassess
AdamaxnootropicBDNFcognitive enhancementneuroprotectionSemax analogbrain health
Dosing & Reconstitution Guide
Start with the lowest recommended dose (300 mcg) to assess individual tolerance. Adamax can cause insomnia and anxiety in sensitive individuals; avoid dosing after 2 PM. Do not exceed 1000 mcg daily without medical supervision. Limited long-term human safety data exists.
Standard / Gradual Approach
10mg VialGradual Introduction (Intranasal)PhaseDoseVolume
1300 mcg daily
2300 mcg daily
3500 mcg daily
4500 mcg daily
5750 mcg daily
61000 mcg daily
Standard / Gradual Approach
10mg VialGradual Introduction (Subcutaneous)PhaseDoseVolume
1100 mcg daily
2200 mcg daily
3300 mcg daily
4300-500 mcg daily
Protocol Summary
Intranasal Spray: daily · Dose range 300–1000 mcg with gradual titration
Subcutaneous Injection: daily · Dose range 100–500 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
Intranasal Spray
Can be used daily without cycling; however, some users rotate 5 days on / 2 days off to prevent tolerance development. Nasal mucosa health should be monitored during extended use.
Subcutaneous Injection
Daily administration recommended without cycling for cognitive support. Some protocols suggest 3 weeks on / 1 week off for tolerance management.
🧪 Quick Start
Vial Size
10 mg
BAC Water
3 mL
Concentration
3.33 mcg/unit
Starting Dose
300 mcg daily
Maintenance Dose
500 mcg daily
Potential Benefits & Use Cases
Adamax is a research chemical intended for laboratory use only and is not approved by the FDA for human consumption. It is sold as a peptide for research purposes. Users assume all responsibility for its use.
Upregulates brain-derived neurotrophic factor (BDNF) and enhances hippocampal TrkB receptor sensitivity (Preclinical)
Modulates dopamine, norepinephrine, and serotonin for improved mood and focus (Preclinical)
Provides neuroprotection through antioxidant and anti-inflammatory mechanisms (Preclinical)
Stabilizes microtubules through ADNP-derived mechanisms supporting neuronal integrity (Preclinical)
Enhanced blood-brain barrier penetration and endurance compared to Semax analogs (Preclinical)
May improve neurological recovery post-stroke based on Semax clinical evidence (Phase II)
Supports cognitive function, memory formation, and neuroplasticity (Preclinical)
Clinical data Strong preclinical Limited data
Mechanism of Action
→Upregulates BDNF (brain-derived neurotrophic factor) expression in hippocampus and cortex
→Enhances TrkB receptor sensitivity for improved neurotrophin signaling
→Modulates monoamine neurotransmitter levels (dopamine, norepinephrine, serotonin)
→Activates neuroprotective pathways reducing oxidative stress
→Stabilizes microtubules through ADNP-derived mechanisms
→Reduces excitotoxicity through neuromodulation
→Enhanced blood-brain barrier penetration via adamantane modification
Lifestyle & Optimization
timing
Avoid late-day dosing to prevent sleep disruption.
diet
Nutrient-dense diet rich in antioxidants. Adequate hydration.
exercise
Regular aerobic exercise.
sleep
Adequate sleep (7–9 hours). Stable circadian rhythm. Stress management supports neuroprotective benefits.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Study TitleType
Side Effects & Safety
Common Side Effects
• Nasal irritation or congestion (intranasal administration)
• Mild headache (usually transient)
• Slight insomnia if dosed late in the day
Contraindications & Warnings
• May cause anxiety or overstimulation at high doses
• Risk of sleep disruption if taken in evening
• Limited long-term human safety data available
Long-Term Safety Data
• Long-term safety profile unknown in humans
• Extrapolated from Semax clinical experience only
🧮 Dose Calculator
Concentration
33.3
mcg/unit
Draw Volume
15
units (0.150 mL)
For a 500 mcg dose, draw 15 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
High bioavailability via subcutaneous injection, bypasses first-pass metabolism and blood-brain barrier restrictions via receptor-mediated transport.
Oral Administration
Not available orally - peptide degradation in GI tract prevents absorption.
Half-Life
2-4 hours (intranasal); 6-8 hours (subcutaneous)
Degradation
Enzymatic degradation by serum proteases; slower degradation than native Semax due to adamantane modification.
Tissue Specificity
CNS-specific distribution with high hippocampal, cortical, and striatal accumulation.
⚗️
Peptide Details
Molecular Weight
1568
Formula
C72H111N21O13
Sequence
Ac-SEMAX-Adamantyl
⚖️
Legal Status & Regulatory
RegionStatus
FDANot Approved - Research Chemical
EUNot Approved - Research Chemical
AustraliaNot Approved - Research Chemical
CanadaNot Approved - Research Chemical
Storage Instructions
Lyophilized (Powder)
Store at -20°C (-4°F) in a cool, dark place away from light and moisture. Stability of 2+ years when properly stored.
Reconstituted (Mixed)
Refrigerate at 2-8°C (35.6-46.4°F) after reconstitution with bacteriostatic water. Use within 2-4 weeks. Discard if solution becomes discolored.